NCT02949219View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

December 31, 2024

Conditions
Metastatic Small Intestinal AdenocarcinomaRecurrent Small Intestinal CarcinomaUnresectable Small Intestinal Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

20007

MedStar Georgetown University Hospital, Washington D.C.

55905

Mayo Clinic, Rochester

57701

Rapid City Regional Hospital, Rapid City

63110

Washington University School of Medicine, St Louis

77030

M D Anderson Cancer Center, Houston

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER